Applying AI to adverse event case processing
October 15, 2025
Qinecsa Chief Operating Officer, John Cogan, has been featured in Chimica Oggi Chemistry Today’s latest issue, where he discusses the impact of new therapy areas
Qinecsa Chief Operating Officer, John Cogan, has been featured in Chimica Oggi Chemistry Today’s latest issue, where he discusses the impact of new therapy areas
Qinecsa VP Product Management QVW, Jonathan Messer, has been featured in Drug Discovery World’s latest issue, where he discusses that the rise in global regulatory
Qinecsa COO, John Coganr, has been featured in The Journal of mHealth’s latest issue, where he discusses that small pharma companies don’t need state-of-the-art systems
Qinecsa COO, John Cogan, has been featured in The Pharma Navigator’s latest issue, where he discusses that increasing the use of advanced technologies will support
Qinecsa COO, John Cogan, has been featured in Pharmaceutical Outsourcing’s latest issue, where he discusses why adverse event case processing is an enormous cost center
Qinecsa CEO, Adam Sherlock, has been featured in Pharma Times’ latest issue, where he discusses how embracing next-generation, AI-driven process automation supports pharma with ongoing
Qinecsa CEO, Adam Sherlock, has been featured in Pharma Tech Outlook Europe’s latest issue, where he discusses how turning pharmacovigilance from a reactive function into
Qinecsa COO, John Cogan, has been featured in European Pharmaceutical Manufacturer‘s latest article, where he discusses AI’s relevance in powering the pharmacovigilance engine. As pharmacovigilance
Molecule to Market is a podcast focused on the pharmaceutical and biotech industries, particularly the outsourcing and supply chain side of drug development. Hosted by Raman
Why an AI Enhanced Approach to Pharmacovigilance Case Processing is now Non-negotiable Qinecsa CEO, Adam Sherlock has been featured in Simedics (The Journal of mHealth)